Idiopathic pulmonary fibrosis research hub
36 indexed studies · 21 currently recruiting
- authorisedTherapeutic exploratory (Phase II)
Safety and Tolerability of systemic administration of metformin in patients with Idiopathic Pulmonary Fibrosis (IPF): A randomized, placebo-controlled, double-blind, phase II proof-of-concept study (Met_for_IPF)
This study looks at whether metformin, a well-known diabetes tablet, is safe and helpful for people with idiopathic pulmonary fibrosis (IPF). Researchers want to see if this medicine can reduce lung scarring, improve breathing, and help patients walk further without feeling out of breath.
Germany - recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibrosis (WHISTLE-PF Trial)
The WHISTLE-PF study looks at an experimental tablet called ENV-101 (taladegib) for idiopathic pulmonary fibrosis (IPF). Researchers want to see if this treatment helps protect lung function and improves daily symptoms like coughing, breathlessness, and tiredness over 24 weeks compared to a dummy tablet (placebo).
Belgium · Ireland · Germany - authorisedTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone at 52 Weeks in Adults with Idiopathic Pulmonary Fibrosis (SURPASS-IPF)
This study tests a new medicine called LYT-100 for idiopathic pulmonary fibrosis (IPF). Researchers want to see if it works as well as or better than pirfenidone, an existing treatment, to protect lung capacity over one year. It is open to adults aged 18 and older with IPF.
Greece · Italy · Czechia - authorisedHuman Pharmacology (Phase I)- First administration to humans
Targeting fibrotic tissue with a radioactive-labelled Fibrobody, visible using a full-body PET/CT scan (FibroVision)
The FibroVision study is testing a new type of medical scan to detect organ scarring, also known as fibrosis. Participants receive a small injection of a specialised tracer called a Fibrobody, followed by a full-body PET/CT scan. Researchers want to find out if this scan is safe and effective.
Netherlands - recruitingTherapeutic exploratory (Phase II)
A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis
This study is testing a new medicine, Fipaxalparant, for a lung condition called Idiopathic Pulmonary Fibrosis (IPF). Researchers want to see if it's safe and helps improve lung function over one to two years compared to a dummy pill.
France · Poland · Netherlands - recruitingTherapeutic exploratory (Phase II)
A Phase 2, randomized, double-blind, placebo-controlled, parallel group study (TRANSFORM) to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF)
This study is testing a new medicine, GSK3915393, for a lung condition called Idiopathic Pulmonary Fibrosis (IPF). We want to see if it helps improve breathing and is safe over 26 weeks. Some people will get the new medicine, and others a dummy pill.
Germany · Italy · France - authorisedTherapeutic exploratory (Phase II)
Proof-of-principle study of inhaled pulmonary surfactant in patients with Idiopathic Pulmonary Fibrosis (INSURF-IPF)
This study explores a new inhaled treatment for Idiopathic Pulmonary Fibrosis (IPF). It aims to see if a special lung surfactant can improve how well your lungs work. Researchers will monitor lung function and safety in adults with IPF.
Germany - recruitingHuman Pharmacology (Phase I)- Other
Evaluation of the value of 18F-Fluoromisonidazole (18F-FMISO) positron emission tomography hypoxia imaging in idiopathic pulmonary fibrosis - A non-randomized proof-of-concept study comparing patients with idiopathic pulmonary fibrosis and healthy subjects
This study is looking at a special scan called 18F-FMISO PET in people with a lung condition called idiopathic pulmonary fibrosis (IPF) and healthy volunteers. It checks if the scan can show areas of low oxygen in the lungs, which might help us understand IPF better.
France - recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (TETON-2)
This study is looking at a new inhaled medicine, treprostinil, for people with Idiopathic Pulmonary Fibrosis (IPF). Researchers want to see if it helps improve lung function and overall health compared to a dummy medicine. It's a large study involving many people.
Belgium · Germany · Denmark - recruitingTherapeutic exploratory (Phase II)
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety and tolerability of different doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF).
This study is testing a new medicine, BI 1819479, for idiopathic pulmonary fibrosis (IPF). We want to see if it can slow down the lung scarring and if it's safe. Some people will get the medicine, others a dummy pill. We'll check how your breathing changes over about a year.
Norway · Germany · Italy - active not recruitingPHASE3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
This study looks at a long-term treatment called nerandomilast for people with pulmonary fibrosis. It's for those who've used it in a past study. We'll see how safe and effective it is over time, checking if it helps lung function and slows down the disease.
United States · Argentina · Australia - active not recruitingPHASE3
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
This study is looking at a new medicine called BMS-986278 for a lung condition called Idiopathic Pulmonary Fibrosis (IPF). It aims to see how well it works, if it's safe, and if people can tolerate it.
United States · Argentina · Australia - completed
Study to investigate longitudinal changes in breath biomarkers in idiopathic pulmonary fibrosis
This study looks at whether a simple breath test can monitor idiopathic pulmonary fibrosis (IPF), a serious lung scarring condition. Researchers will analyse chemical patterns in exhaled breath over time. This could help doctors track disease progression and check how well treatments are working without requiring uncomfortable or invasive tests.
United Kingdom · England - completedPhase III
Treating people with idiopathic pulmonary fibrosis with the addition of lansoprazole (TIPAL)
Idiopathic pulmonary fibrosis (IPF) causes lung scarring, breathlessness, and coughing. Many people with IPF also have acid reflux, which may damage the lungs further. The TIPAL study tests whether taking lansoprazole, a common medicine for heartburn, can slow down lung damage. Participants take either lansoprazole or dummy tablets for one year.
United Kingdom · England · Northern Ireland - recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Efficacy and Safety of MBS2320 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This study is testing a new medicine, MBS2320, for a lung condition called Idiopathic Pulmonary Fibrosis (IPF). We want to see if it helps improve breathing and if it's safe to use. Some people will get the medicine, and some will get a dummy pill, to compare the results.
France · Spain · Italy - recruitingTherapeutic confirmatory (Phase III)
Pragmatic management of progressive disease in idiopathic pulmonary fibrosis: a randomized trial. PROGRESSION-IPF
This study looks at how well different medicines treat Idiopathic Pulmonary Fibrosis (IPF). It compares two common drugs, Esbriet and Ofev, to see which helps slow down the disease’s progress and if people can take them easily. It aims to find the best ways to manage IPF.
France - recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis
This study is testing a new inhaled medicine, ARO-MMP7, for people with a serious lung condition called idiopathic pulmonary fibrosis (IPF). It's an early stage trial to see if the medicine is safe and how it works in healthy volunteers and those with IPF.
Spain · Denmark · Italy - recruitingTherapeutic exploratory (Phase II)
A participant - and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in patients with idiopathic pulmonary fibrosis
This study is looking into new treatments for Idiopathic Pulmonary Fibrosis (IPF). It compares a new medicine, LTP001, with a dummy pill (placebo) to see if it can slow down the lung disease and improve how people feel, checking for safety and side effects along the way.
Germany · Czechia · Netherlands - recruitingHuman Pharmacology (Phase I)- Other
A phase 1, randomised, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics in healthy adult subjects after subcutaneous injection of TISA-818-Inj-5mg/mL.
This study is testing a new medicine, TISA-818, for idiopathic pulmonary fibrosis (a lung scarring condition). It's an early-stage study to check if the medicine is safe, how well people tolerate it, and how the body handles it after injections in healthy adults.
Sweden - recruitingPHASE2
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
This study is testing a new medicine called CHF10067 (Zampilimab) for Idiopathic Pulmonary Fibrosis (IPF). We want to find out if it's safe and effective at different doses over 24 weeks for people living with this lung condition.
United States · North Macedonia · South Korea - recruitingPHASE2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
This study is testing a new medicine, PIPE-791, for a lung condition called Idiopathic Pulmonary Fibrosis (IPF). We want to see how well it works, if it's safe, and if people can tolerate it. It's a phase 2 study, meaning we're still in the early stages of testing.
Argentina · Australia · Canada - active not recruitingPHASE2
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
This study, called WISPer, is testing a new medicine called MTX-463 for Idiopathic Pulmonary Fibrosis (IPF). It's comparing MTX-463 to a dummy medicine (placebo) to see if it's safe and effective for people with this lung condition.
United States · Argentina · Australia - recruitingPHASE1
NAL ER IPF Respiratory Function and Safety Study
This study is looking at a new medicine called NAL ER for people with Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the medicine is safe, what doses people can tolerate, and if it helps with breathing.
United States · United Kingdom - recruitingPHASE2
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
This study looks at a new medicine, BI 765423, for Idiopathic Pulmonary Fibrosis (IPF). It aims to see if this medicine can improve lung function in adults with IPF, comparing it to a dummy treatment over three months.
United States · Australia · Belgium - recruiting
Effects of Pulmonary Diseases and Their Treatment on Cardiac Function
This study looks at how long-term lung diseases like COPD, asthma, or lung scarring affect the heart, especially the left side. Researchers will use special scans to see if treatments for lung problems also help the heart, aiming for better care.
Germany - active not recruitingPHASE2
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
This study is testing a new medicine called CAL101 for Idiopathic Pulmonary Fibrosis (IPF). It aims to see if CAL101 can help stop lungs from getting worse in adults with IPF, compared to a dummy treatment.
United States · Denmark · France - recruitingPHASE2
Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease
This study looks into a new drug called Senicapoc for people with lung scarring diseases like pulmonary fibrosis. Researchers want to see if Senicapoc can stop the scarring from getting worse, compared to a dummy pill. It involves taking pills for 26 weeks and having check-ups.
Denmark · Estonia · United Kingdom - recruitingPHASE3
Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole
This study looks at whether a stomach acid medicine, lansoprazole, can help people with Idiopathic Pulmonary Fibrosis (IPF). IPF causes lung scarring, and stomach acid reflux might make it worse. We want to see if this medicine can slow down IPF progression and help patients feel better.
United Kingdom - active not recruiting
Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
This study collects information and samples from people with rare lung conditions, including Idiopathic Pulmonary Fibrosis (IPF). It aims to understand these diseases better and help find new treatments. It's a Europe-wide effort to improve care for patients.
Austria · France · Germany - active not recruitingPHASE2
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
This study is looking at a new medicine called axatilimab for people with Idiopathic Pulmonary Fibrosis (IPF). We want to see if it's safe and effective in slowing down this lung condition. It's a Phase 2 trial, meaning it's still in earlier stages of testing.
Australia · Belgium · Canada - active not recruiting
Changes in iOS in IPF
This study looks at a new way to measure lung health in people with Idiopathic Pulmonary Fibrosis (IPF). It explores if a test called impulse oscillometry (iOS) can give clear, useful information about how IPF affects the lungs and predict if it might get worse, potentially making monitoring easier.
United Kingdom - enrolling by invitationPHASE3
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
This study looks at the long-term effects of an inhaled medicine called treprostinil for people with certain lung scarring conditions like Idiopathic Pulmonary Fibrosis. It follows people who've already been part of similar studies to see how safe and helpful the treatment is over time.
United States · Argentina · Australia - active not recruitingPHASE2
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
This study is testing a new medicine, ENV-101, for people with lung scarring conditions like Idiopathic Pulmonary Fibrosis (IPF). It aims to see if it improves breathing and is safe to use. Patients might continue their usual treatments.
Argentina · Australia · Austria - authorisedTherapeutic exploratory (Phase II)
A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects with Idiopathic Pulmonary Fibrosis
This study is looking into new treatments for Idiopathic Pulmonary Fibrosis (IPF), a serious lung condition. Researchers will compare a new medicine with a dummy treatment to see if it can improve lung function over 24 weeks. It's for adults with IPF.
Greece · Italy · Sweden - recruitingNA
Pilot Study of Nitrate-rich Beetroot Juice Supplementation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This study looks at whether nitrate-rich beetroot juice can help people with a lung condition called Idiopathic Pulmonary Fibrosis (IPF) breathe and exercise more easily. We want to see if it boosts their exercise ability and changes certain substances in their blood.
United Kingdom - recruitingPHASE2
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
This study is looking into a new treatment called ABBV-142 for a lung condition called Idiopathic Pulmonary Fibrosis (IPF). It aims to check if the new drug is safe, what side effects it might cause, and if it helps improve the condition compared to a dummy drug.
United States · Australia · Bulgaria